
Boeing is in advanced discussions with a newly created Indian budget carrier to sell 737 MAX jets, according to people familiar with the matter, a deal that could give the US planemaker a crucial breakthrough in a major market dominated by Airbus.
The airline, Akasa, backed by billionaire investor Rakesh Jhunjhunwala, has also held discussions with Airbus for its best-selling A320neo jets, but that model isn’t available for delivery until several years down the track, tilting the equation in Boeing’s favor, the people said, asking not to be identified because the matter is confidential.
The talks aren’t finalized and could still fall apart, the people said. Akasa, which is seeking initial approval from India’s aviation ministry, plans to use sale-and-leaseback deals to finance the planes, one of the people said. This would allow the new airline to receive cash from leasing firms as it takes possession of the jets.
Jhunjhunwala’s new airline is looking at operating a fleet of 70 aircraft in four years, the businessman said in a Bloomberg Television interview last month. An order for 70 units of 737 MAX-8 jets — the most popular model — would be valued at US$8.5 billion at sticker prices, although discounts are common in large plane orders. Boeing is likely to offer steeper-than-usual discounts on this deal, the people said.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas